UNITY Biotechnology Files for Voluntary Dissolution, Begins Liquidation Process After Shareholder Approval

Reuters09-27

UNITY Biotechnology Files for Voluntary Dissolution, Begins Liquidation Process After Shareholder Approval

UNITY Biotechnology Inc. has taken key steps in its dissolution process, recently entering into a Lease Termination Agreement with Bayside Area Development, LLC for its South San Francisco office and laboratory space. The lease, originally set to expire at the end of 2029, will now terminate effective March 31, 2026. Additionally, the company filed a certificate of dissolution with the Delaware Secretary of State on September 26, 2025, which became effective the same day. As part of the dissolution plan, UNITY Biotechnology has closed its transfer books, and shares of its common stock are no longer assignable or transferable except in limited circumstances related to inheritance or operation of law.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UNITY Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-220778), on September 26, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2570370148?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-27 05:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570370148","market":"nz","top_or_hot":-1,"title":"UNITY Biotechnology Files for Voluntary Dissolution, Begins Liquidation Process After Shareholder Approval","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      UNITY Biotechnology Files for Voluntary Dissolution, Begins Liquidation Process After Shareholder Approval\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        UNITY Biotechnology Inc. has taken key steps in its dissolution process, recently entering into a Lease Termination Agreement with Bayside Area Development, LLC for its South San Francisco office and laboratory space. The lease, originally set to expire at the end of 2029, will now terminate effective March 31, 2026. Additionally, the company filed a certificate of dissolution with the <a href=\"https://laohu8.com/S/VMM\">Delaware</a> Secretary of State on September 26, 2025, which became effective the same day. As part of the dissolution plan, UNITY Biotechnology has closed its transfer books, and shares of its common stock are no longer assignable or transferable except in limited circumstances related to inheritance or operation of law.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UNITY Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-220778), on September 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UNITY Biotechnology Files for Voluntary Dissolution, Begins Liquidation Process After Shareholder Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUNITY Biotechnology Files for Voluntary Dissolution, Begins Liquidation Process After Shareholder Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-27 05:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      UNITY Biotechnology Files for Voluntary Dissolution, Begins Liquidation Process After Shareholder Approval\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        UNITY Biotechnology Inc. has taken key steps in its dissolution process, recently entering into a Lease Termination Agreement with Bayside Area Development, LLC for its South San Francisco office and laboratory space. The lease, originally set to expire at the end of 2029, will now terminate effective March 31, 2026. Additionally, the company filed a certificate of dissolution with the <a href=\"https://laohu8.com/S/VMM\">Delaware</a> Secretary of State on September 26, 2025, which became effective the same day. As part of the dissolution plan, UNITY Biotechnology has closed its transfer books, and shares of its common stock are no longer assignable or transferable except in limited circumstances related to inheritance or operation of law.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UNITY Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-220778), on September 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UNBX","symbol_name":"Unity Biotechnology, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nNDLPpJpM:1","article_id":"2570370148","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570370148","pubTimestamp":1758920960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"UNITY Biotechnology Inc. has taken key steps in its dissolution process, recently entering into a Lease Termination Agreement with Bayside Area Development, LLC for its South San Francisco office and laboratory space. The lease, originally set to expire at the end of 2029, will now terminate effective March 31, 2026. Additionally, the company filed a certificate of dissolution with the Delaware Secretary of State on September 26, 2025, which became effective the same day. As part of the dissolution plan, UNITY Biotechnology has closed its transfer books, and shares of its common stock are no longer assignable or transferable except in limited circumstances related to inheritance or operation of law.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or leg","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"UNBX":"Unity Biotechnology, Inc.","UBX":"Unity Biotechnology","BK4139":"生物科技","BK4203":"医疗保健房地产投资信托","BK4225":"医疗保健房地产信托","DOC":"Healthpeak Properties, Inc","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"UNITY Biotechnology申请自愿解散，股东批准后开始清算程序","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DOC":0.9,"UBX":0.9,"UNBX":0.9},"content_text":"UNITY Biotechnology Files for Voluntary Dissolution, Begins Liquidation Process After Shareholder Approval\n    \n\n        UNITY Biotechnology Inc. has taken key steps in its dissolution process, recently entering into a Lease Termination Agreement with Bayside Area Development, LLC for its South San Francisco office and laboratory space. The lease, originally set to expire at the end of 2029, will now terminate effective March 31, 2026. Additionally, the company filed a certificate of dissolution with the Delaware Secretary of State on September 26, 2025, which became effective the same day. As part of the dissolution plan, UNITY Biotechnology has closed its transfer books, and shares of its common stock are no longer assignable or transferable except in limited circumstances related to inheritance or operation of law.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UNITY Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-220778), on September 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"corporation,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2570370148","isCrawlerRequest":true}